(Q37777491)

23 August 2017

1 reference

title

Maintaining bone health in prostate cancer throughout the disease continuum (English)

1 reference

23 August 2017

Maintaining Bone Health in Prostate Cancer Throughout the Disease Continuum (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

16 June 2024

1 reference

1

Fred Saad

1 reference

23 August 2017

James Eastham

2

1 reference

23 August 2017

language of work or name

1 reference

1 June 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410000862?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

https://api.elsevier.com/content/article/PII:S0093775410000862?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

16 June 2024

1 reference

23 August 2017

volume

37 Suppl 1

1 reference

23 August 2017

page(s)

S30-7

1 reference

EAU guidelines on prostate cancer

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss

16 June 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

16 June 2024

5

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

16 June 2024

6

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer

16 June 2024

9

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Pathologic fractures correlate with reduced survival in patients with malignant bone disease

16 June 2024

12

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial

16 June 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy

16 June 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors

16 June 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

16 June 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

16 June 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients

16 June 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Clodronate for treatment of bone metastases in hormone refractory prostate cancer

16 June 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

16 June 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

New research findings on zoledronic acid: survival, pain, and anti-tumour effects

16 June 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

16 June 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer

16 June 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer

16 June 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer

16 June 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer

16 June 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer

16 June 2024

47

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate

16 June 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells

16 June 2024

53

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

16 June 2024

54

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation

16 June 2024

55

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.

16 June 2024

56

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

16 June 2024

58

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.007

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference